KEYNOTE-189 data presentation
KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC including 5-year pooled analysis for squamous and non-squamous PD-L1 TPS <1% mNSCLC

Download our KEYNOTE-189 slide deck that discusses KEYTRUDA + plat-pem clinical data in metastatic non-squamous untreated NSCLC in adults whose tumours have no EGFR- or ALK-positive mutations.

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).

Find out more information about KEYTRUDA in metastatic NSCLC:

Visit product page

Supporting documentation

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.

KEYNOTE-189 data presentationKEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC including 5-year pooled analysis for squamous and non-squamous PD-L1 TPS <1% mNSCLC

Supporting documentation

For UK Healthcare Professionals

KEYNOTE-189 data presentation
KEYTRUDA® (pembrolizumab), in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic, non-squamous NSCLC including 5-year pooled analysis for squamous and non-squamous PD-L1 TPS <1% mNSCLC